STROBER , B.; ASAHINA, A.; MROWIETZ, U.; LEBWOHL, M.; FOLEY, P.; LANGLEY, R.; BARKER, J.; CIOFFI, C.; CROSS, N.; WANG, M. .; PAUL, C. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s52, 2021. DOI: 10.25251/skin.5.supp.52. Disponível em: Acesso em: 20 jul. 2024.